GUJARAT THEMIS BIOSYN LTD Dividend 2024 Record Date, Share Price, History

News: Gujarat Themis Biosyn Ltd., a prominent pharmaceutical company, has recently made headlines with its dividend announcement for the year 2024. In this article, we’ll delve into the details of the dividend, the record date, the company’s share price, and a brief history.

Dividend Announcement

On February 12, 2024, Gujarat Themis Biosyn declared an interim dividend of Rs. 0.75 per share. This dividend reflects the company’s commitment to rewarding its shareholders.

Record Date

The record date for this dividend is February 22, 2024. If you own shares of Gujarat Themis Biosyn on or before this date, you’ll be eligible to receive the dividend.

Share Price Movement

Investors are closely watching Gujarat Themis Biosyn’s share price. As of now, the company’s stock price has been on an upward trajectory. The record date for the dividend (February 22, 2024) may impact the share price, so keep an eye on the market developments.

About GUJARAT THEMIS BIOSYN LTD :

Gujarat Themis Biosyn Ltd (GTBL) is a remarkable Indian pharmaceutical company that has left an indelible mark in the industry. Let’s delve into its fascinating journey and contributions.

Gujarat Themis Biosyn has a rich history in the pharmaceutical sector. Established in India, the company has consistently focused on research, development, and production of high-quality medicines. Its commitment to innovation and patient well-being has contributed to its success over the years.

Founding and Early Days

GTBL was incorporated in 1981 as a joint venture between GIIC Ltd. and Chemosyn (P) Ltd. Its mission? To produce life-saving drugs that would impact millions of lives. And it did just that.

A Trailblazer in Tuberculosis Treatment

GTBL holds the distinction of being India’s first company to start commercial production of the anti-tuberculosis drug Rifampicin. This breakthrough drug has been instrumental in combating tuberculosis, a disease that affects millions worldwide.

Erythromycin and Beyond

In August 1985, GTBL commenced production, initially focusing on Erythromycin and Erythromycin salts and formulations. These antibiotics have been crucial in treating various infections.

Subscribe to Sarkari Result to stay informed. Get the latest celebrity news and detailed movie reviews in real-time. Keep up with the constantly changing world of entertainment with Sarkari Exam.

Ownership and Consortium

In 1991, GTBL was taken over by the Yuhan Group from South Korea and the Pharmaceutical Business Group (India) Ltd. (PBG). The PBG is a unique consortium of five competing drug companies, including Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus), and Lyka Labs Ltd.

Current Management

Since 2007, GTBL has been actively managed by Themis Medicare Ltd., a joint venture company of Gedeon Richter Ltd. (Hungary). Their commitment to excellence continues to drive GTBL’s success.

Gujarat Themis Biosyn’s dividend announcement is a positive sign for shareholders. If you’re invested in the company, mark your calendar for the record date and stay informed about any further updates. As the pharmaceutical industry continues to evolve, Gujarat Themis Biosyn remains a key player in shaping healthcare solutions.

Disclaimer: Please note that all content and tools on this website are provided for your convenience and are offered “as is” without warranties. The information provided, including any tool-generated output, is for informational purposes only and should not be considered investment advice or guarantees. Exercise caution, seek professional advice, and make independent judgments before acting on any information found on this site.